178 related articles for article (PubMed ID: 22878366)
1. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.
Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ
Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366
[TBL] [Abstract][Full Text] [Related]
2. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
[TBL] [Abstract][Full Text] [Related]
3. Assessment of mitotic rate reporting in melanoma.
Burton AL; Egger ME; Gilbert JE; Stromberg AJ; Hagendoorn L; Martin RC; Scoggins CR; McMasters KM; Callender GG
Am J Surg; 2012 Dec; 204(6):969-74; discussion 974-5. PubMed ID: 23036603
[TBL] [Abstract][Full Text] [Related]
4. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
5. Morphologic Forms and Classification of Dermal Mitotic Figure Density in Primary Cutaneous Melanoma: A Retrospective Study.
Marsch AF; McKee RM; Hinds BR
Am J Dermatopathol; 2020 Jan; 42(1):35-40. PubMed ID: 31884499
[TBL] [Abstract][Full Text] [Related]
6. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
7. Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one.
Sekula-Gibbs SA; Shearer MA
Dermatol Surg; 2011 Aug; 37(8):1080-8. PubMed ID: 21635622
[TBL] [Abstract][Full Text] [Related]
8. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
9. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.
Ponti G; Pollio A; Cesinaro AM; Pellacani G; Magnoni C; Seidenari S
Cancer Epidemiol; 2012 Jun; 36(3):303-5. PubMed ID: 22153914
[TBL] [Abstract][Full Text] [Related]
10. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
11. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
12. Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain.
Ottmann K; Tronnier M; Mitteldorf C
J Am Acad Dermatol; 2015 Oct; 73(4):637-44. PubMed ID: 26278815
[TBL] [Abstract][Full Text] [Related]
13. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
[TBL] [Abstract][Full Text] [Related]
14. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy?
Kirkland EB; Zitelli JA
Dermatol Surg; 2014 Sep; 40(9):937-45. PubMed ID: 25072127
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
16. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract][Full Text] [Related]
17. Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma.
de Waal AC; van Harten-Gerritsen AS; Aben KK; Kiemeney LA; van Rossum MM; Blokx WA
Br J Dermatol; 2014 Apr; 170(4):874-7. PubMed ID: 24593233
[TBL] [Abstract][Full Text] [Related]
18. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
[TBL] [Abstract][Full Text] [Related]
19. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.
Piñero-Madrona A; Ruiz-Merino G; Cerezuela Fuentes P; Martínez-Barba E; Rodríguez-López JN; Cabezas-Herrera J
Clin Transl Oncol; 2019 Oct; 21(10):1348-1356. PubMed ID: 30783917
[TBL] [Abstract][Full Text] [Related]
20. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
Barnhill RL; Katzen J; Spatz A; Fine J; Berwick M
J Cutan Pathol; 2005 Apr; 32(4):268-73. PubMed ID: 15769275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
